Image-based modelling of inhaler deposition during respiratory exacerbation

³ Josh Williams^a, Jari Kolehmainen^b, Steve Cunningham^c, Ali Ozel^{a,*}, Uwe Wolfram^{a,*}

^a School of Engineering and Physical Sciences, Heriot-Watt University, Edinburgh, UK
 ^b Department of Chemical and Biological Engineering, Princeton University, Princeton, New Jersey, USA
 ^c Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK

7 Abstract

1

2

For many of the one billion sufferers of respiratory diseases worldwide, managing their 8 disease with inhalers improves their ability to breathe. Poor disease management and ris-9 ing pollution can trigger exacerbations which require urgent relief. Higher drug deposition 10 in the throat instead of the lungs limit the impact on patient's symptoms. To optimise de-11 livery to the lung, patient-specific computational studies of aerosol inhalation can be used. 12 However in many studies, inhalation modelling does not represent an exacerbation, where 13 the patient's breath is much faster and shorter. Here we compare differences in deposition 14 of inhaler particles in the airways of a healthy male, female lung cancer and child cystic 15 fibrosis patient. We aimed to evaluate deposition differences during an exacerbation with 16 image-based healthy and diseased patient models. We found that during an exacerbation, 17 particles progressing to the lower airways were distributed similarly to those inhaled dur-18 ing healthy breathing, but fewer in quantity. Throat deposits were halved in the healthy 19 patient compared to the diseased patients under extreme inhalation, due to changes in the 20 detailed shape of the throat. Our results identify that the modelled upper airway must be 21 patient-specific, and an exacerbating profile tested for optimal measurement of reliever in-22 haler deposition. 23

24 Keywords: Drug delivery, Respiratory exacerbation, Patient-specific medicine, Dosimetry,

²⁵ Cystic fibrosis, Aerosol deposition

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

*Corresponding authors share last authorship

Email addresses: a.ozel@hw.ac.uk (Ali Ozel), u.wolfram@hw.ac.uk (Uwe Wolfram)

26 1. Introduction

More than one billion people worldwide suffer from asthma, cystic fibrosis, and other 27 chronic respiratory diseases (The Global Asthma Network, 2018), many experiencing dis-28 tress and anxiety due to restrictions to activities and limited productivity (Dockrell et al., 29 2007). These limitations are most prominent among the young and elderly (The Global 30 Asthma Network, 2018). One of the largest contributors to the diseased population is asthma, 31 which incurs an annual cost per patient of €1,700 and \$3,100 in Europe and the USA, re-32 spectively (Nunes et al., 2017) from direct cost of treatment and indirect costs such as work 33 absence or decreased productivity (Katsaounou et al., 2018; Gruffydd-Jones et al., 2019). 34 Similar impacts are induced from cystic fibrosis, a highly common hereditary disease in the 35 UK, USA and Australia (Elborn, 2016). Consistent treatment in alignment with disease man-36 agement plans are recommended to minimise symptoms (Ring et al., 2015), but adherence 37 is an issue in young patients (McQuaid et al., 2003) and many adults are purposely incon-38 sistent to limit exposure to side-effects such as osteoporosis and cataracts (Dockrell et al., 39 2007). Even in adherent patients, efficiency of the metered-dose inhaler varies greatly across 40 patients (Clark, 1995) as many (particularly children) experience difficulties in device tech-41 nique (Usmani, 2019) due to the rapid spray of the drug. The issue of technique (patient 42 breathing pattern and coordination with device actuation) and differences in lung structure 43 are the main influences in drug delivery (Darquenne et al., 2016). 44

Optimisation of the medication deposition could be achieved through *in silico* analyses, 45 by providing the clinician information on the local deposition and therapeutic outcome. One 46 available deposition tool is the Multiple-Path Particle Dosimetry (MPPD) model (Anjilvel 47 and Asgharian, 1995; Asgharian et al., 2001). However this calculates deposition of ambient 48 particles (Borghardt et al., 2015), which does not mirror the physics of spray aerosol inhala-49 tion (Longest et al., 2008). This issue has been recognised and a commercial counterpart to 50 predict deposition of pharmaceutical aerosols has been developed (Olsson and Bäckman, 51 2018). However, as the equations used are based on probabilistic 1D equations, similar to 52 that of MPPD, complex fluid phenomena and particle interactions cannot be included. Com-53 parisons between 1D models and computational particle-fluid dynamics (CPFD) deposition 54 led Zhang et al. (2009) to observe significant differences in local deposition, attributed to 55

local flow. Flow and particle phenomena can be readily accounted for in CPFD by solving 56 equations governing the transport of air and particles (e.g. see (Sundaresan et al., 2018)). 57 Flow can be solved in airways extracted from medical images and particle properties can 58 represent inhaler particles to produce patient-specific deposition analyses. But with the 59 complexity of the flow regimes in the system creating demanding simulations and the mas-60 sive number of respiratory patients, the benefit to cost of image-based modelling is an issue. 61 Work exists interpreting pharmaceutical deposition differences in adult patients (van Hols-62 beke et al., 2018; Poorbahrami and Oakes, 2019; Poorbahrami et al., 2019), but only sparse 63 research models deposition in children. Existing children-focused image-based deposition 64 studies analyse the nasal cavity (Xi et al., 2011, 2012) or central airways (Das et al., 2018; 65 Oakes et al., 2018). To move towards enhanced treatments for all ages, a study consider-66 ing the impact of the upper airways is needed. We begin this by comparison of deposition 67 in the airways (from mouth to central airways) in three diverse patients ranging from 11 – 68 49 years old. This can allow simulation of flow created in the upper airways and provide 69 understanding of how this affects deposition throughout the airways, across patients. 70

Results from these simulations are dependent on the inflow conditions, which here is 71 based on the duration and strength of the patient's inhalation. Colasanti et al. (2004) pub-72 lished breathing profiles of patients who had recently had an exacerbation (around one hour 73 before measurements were taken) show vastly different shape and magnitude from the in-74 halation waveform which is typically used in respiratory CPFD studies (Inthavong et al., 75 2010). A sinusoidal inhalation waveform is used by most existing studies (Oakes et al., 2018; 76 Inthavong et al., 2010; Naseri et al., 2017), which mimics a healthy patient's tidal breathing. 77 The variation in flow patterns produced by these differences would therefore give a de-78 position analysis which may not represent the reliever inhaler's true operating conditions. 79 Different breathing profiles have been utilised (Longest et al., 2012; Khajeh-Hosseini-Dalasm 80 and Longest, 2015), but these were used to represent techniques for different devices (dry-81 powder compared to metered-dose inhalers), not exacerbating and healthy breathing in a 82 metered-dose inhaler. By applying different inflow conditions, one can understand changes 83 in flow structure during an exacerbation or another desired breathing situation. This knowl-84 edge would allow manufacturers to tailor inhaled therapeutics to ensure optimal dosage 85

reaches the desired site in the airways, and to provide clinicians and patients the tools with
which to maximise inhalation technique during exacerbations.

In addition, existing MDI deposition research simplifies particle interactions, which in-88 cludes treating particle-wall collision as complete sticking. This is a coarse approximation of 89 dissipative lubrication forces between the particle and wall (Legendre et al., 2005; Holbrook 90 and Longest, 2013). To treat as fully sticking therefore neglects rebound and could over-91 estimate deposition of high inertia particles. Furthermore, MDI studies often exclude van 92 der Waals forces which can cause small particles agglomerate (Hamaker, 1937), and become 93 more inertial. If the increase in inertia is large enough, this can change particle trajectory 94 or chance of rebound, which, in turn would cause early deposition. How these forces alter 95 deposition and compete against each other should be tested. Applying this to simulations 96 made specific to a patient's airway structure under extreme and optimal breathing will fur-97 ther understanding of drug transport across different health states. 98

Therefore, we aimed to (i) evaluate the need for patient-specific domains in future simulations through medical image-based modelling of three diverse patients. To satisfy this we also aimed to (ii) identify the necessary physical effects to produce accurate models of the system (including the mass of drug simulated, van der Waals and particle-wall lubrication forces), and (iii) evaluate variation in deposition during exacerbating breathing.

104 2. Methods

To answer the research aims above, we evaluated changes in deposition produced by 105 the following variations. Parameters varied included the mass of drug simulated, parti-106 cle cohesiveness, lubrication forces in particle wall-collisions, and deletion or saving of de-107 posited particles from the system to mimic absorbing particles with mucus layer. The use 108 of a healthy and exacerbation breathing profile (Colasanti et al., 2004) allowed for analysis 109 of the reliever inhaler during an exacerbation. The effects of patient variation were then 110 analysed using this optimised modelling setup, through comparison under realistic inflow 111 conditions in three patients. 112

¹¹³ 2.1. Medical image processing

Three patients were studied retrospectively using computed tomography (CT) (detailed
 in Table 1). Use of these retrospective images was approved by Heriot-Watt University (ID:

4

¹¹⁶ 2020-0500-1452). The surface file of the healthy patient's segmented airways was provided

¹¹⁷ by Dr Filippo Coletti (University of Minnesota). The patients had sufficient variation in age,

¹¹⁸ gender and health status to gather an indication of the benefit of patient-specificity.

Table 1: Information of patients studied in this work. Although a small group, variations in gender, age and disease have been included.

Gender	Age	Illness	Voxel size (mm ³)	Source
Male	47	Healthy	$0.977 \times 0.977 \times 2.5$	Zhang et al. (2012),
Female	Unknown (adult)	Lung cancer	$0.977 \times 0.977 \times 3.0$	Banko et al. (2015) Yang et al. (2017)
				Yang et al. (2018) Clark et al. (2013)
Male	11	Cystic fibrosis	$0.5254 \times 0.5254 \times 1.0$	

Images were processed using 3D Slicer 4.10 (Fedorov et al., 2012). Images were pre-119 processed by applying isotropic spacing to account for the anisotropic resolution of CT scans 120 (Table 1). For the cancer patient, voxel size was then reduced using a linear interpolation, 121 creating a voxel size of $\approx 0.4 \,\mathrm{mm}$ to allow extraction of smaller airways. This was also 122 performed on the cystic fibrosis patient. To preserve edges of the airway while blurring 123 lung tissue, an anisotropic diffusion filter was then applied (Duan et al., 2019). Parameters 124 used were conductance 3, 5 iterations and step size of 0.06025. These were based on visual 125 comparison of our segmentations produced from different values of conductance used to 126 good success in medical imaging (Behnaz et al., 2010; Sen et al., 2011). 127

Images were then segmented using a threshold-based region-growing approach to seg-128 ment areas classified as air without leakage to the background air (Nardelli et al., 2015; 129 Mayer et al., 2004; De Nunzio et al., 2011; Aykac et al., 2003). This semi-automatic process 130 grows the segment from 'seeds' which are user declared points within each region, set sep-131 arately for the airway and surrounding lung tissue. Once each region was grown, labels 132 denoting leaked regions were found by overlaying the segmentation on the scan. Leaked 133 regions were then labelled as airway and the region was grown again until the scan was ob-134 served to be acceptable quality. This process was applied to the external airways, right and 135 left lungs separately due to variations in the airway image density in each region (Nardelli 136 et al., 2015). This allowed segmentation to a depth ranging from the fourth to sixth bifurca-137 tion level (G4 – G6, Figure 1). 138



Figure 1: Segmented airway trees of patients included in the study. The airways are presented from left to right as (a) the healthy, male adult (Banko et al., 2015), (b) the adult, female lung cancer patient (Yang et al., 2017, 2018; Clark et al., 2013), and (c,d) the male child cystic fibrosis patient. The child patient has (c) constricted throat added from the cancer patient (b), and (d) has a dilated throat taken from the healthy patient (a). Areas within the dashed box have been artificially added due to available images not including this region.

Some of the upper airways were not included in the CT data, we have found this to be 139 common in most clinical CT scans. To account for this we merged the oral cavity of the 140 healthy patient to the throat of the lung cancer patient. This region was then extracted, 141 scaled and joined to the trachea of the cystic fibrosis patient to complete the missing regions. 142 Scaling was performed such that the intersection of the new and existing regions matched 143 in diameter (resulting in a scaling of 0.8 for the added region). This was later repeated using 144 the throat of healthy patient, after being advised such a narrow, obstructed throat is not 145 characteristic of cystic fibrosis, and likely unique to the cancer patient. The regions which 146 were artificially added are shown graphically in Figure 1 within the dashed box. These 147 excluded regions are of large importance in inhaler simulations as a large portion of the 148 dosage is lost within this part of the airway and the turbulence created here is cascaded 149 through the trachea and main bronchus (Banko et al., 2015). 150

¹⁵¹ 2.2. *Mathematical modelling*

Here we present the mathematical relations used to determine the physical factors included in our model of the system. We provide the equations governing the fluid and particle solvers in Appendix A. Briefly, particle transport was solved by the discrete el-

ement method (DEM) using the particle simulator LIGGGHTS (Kloss and Goniva, 2011). 155 This tracks individual particles' trajectories by integrating Newton's equations of motion 156 in time for each particle (Verlet, 1967). Particle collisions were modelled as a linear spring-157 dashpot system (Cundall and Strack, 1979). Fluid transport through the airways was solved 158 by the volume-filtered mass and momentum continuity equations (Anderson and Jackson, 159 1967; Capecelatro and Desjardins, 2013) implemented in OpenFOAM v2.2 (Weller et al., 160 1998). Particle and fluid phases were coupled through a version of the CFDEMcoupling 161 platform (Kloss et al., 2012) modified to benefit from faster two-way coupling by Ozel et al. 162 (2016). 163

Filtering the fluid transport equations creates unresolved stresses. In our simulations, we consider stress contributions from the gas pressure gradient ($\nabla \bar{p}_f$) and residual stresses from volume filtering of fluid velocity fluctuations (R_u) below the cell size, Δ . R_u is dependent upon the eddy viscosity (μ_t), a term representing turbulence dissipation into the smaller, unresolved scales. Eddy viscosity is modelled using a dynamic Smagorinsky model (Germano et al., 1991; Lilly, 1992). This models the energy transfer to flow structures smaller than the cell size without a fixed model constant, as this is computed dynamically.

¹⁷¹ We solve particle drag from the relation derived by Beetstra et al. (2007) for monodisperse ¹⁷² particles. This drag law is based on the particle's Reynolds number, Re_p , given as

$$Re_p = (1 - \phi) \frac{\rho_f V_{r,i} d_p}{\mu_f}.$$
(1)

¹⁷³ Where $V_{r,i}$ is the relative particle velocity, d_p is the particle diameter, μ_f is the viscosity. As ¹⁷⁴ well as determining particle drag, Re_p also characterises particle inertia through the parti-¹⁷⁵ cle's Stokes number,

$$St = (1 - \phi) \frac{\rho_p \, d_p^2 \, V_{r,i}}{18\mu_f D} = \frac{\rho_p}{\rho_f} \frac{d_p}{18D} \, Re_p.$$
(2)

Where *D* is the airway diameter. Due to their small size, metered-dose inhaler particles
have a Stokes number below one, meaning they show high sensitivity to carrier fluid fluctuations induced by the complex structure of the upper airways (Kleinstreuer and Zhang,
2010). This makes the Stokes number the primary parameter to be adjusted when optimising
deposition (Kleinstreuer and Zhang, 2010).

Again, due to the particle's small size, particle-particle cohesion from van der Waals 181 forces may influence deposition. Particle attractive energy due to van der Waals force is 182 determined by the material's Hamaker constant, A (Hamaker, 1937). To permit a larger 183 timestep, particles' elastic properties are softened. Therefore the real stiffness (k_R) is re-184 duced to a soft stiffness (k_S) , and the Hamaker constant is amended by the relationship 185 $A^S = A^R (k_S / k_R)^{1/2}$ using the model of Gu et al. (2016*a*). This reduction of real particle stiff-186 ness (k_R) to a softer stiffness (k_S) has negligible effect on fluid hydrodynamics and particle 187 cohesion (Gu et al., 2016a; Ozel et al., 2017). To determine A, which is not given in literature 188 for the metered-dose inhaler propellant HFA-134A, we evaluate deposition at three Bond 189 numbers, Bo. Bo is provided by Ozel et al. (2017) as 190

$$Bo = \frac{F_{\text{vdw}}^{\text{max}}}{m_p |\mathbf{g}|} = \frac{A \, d_p}{24 (s_{\min}^R)^2 m_p |\mathbf{g}|}.$$
(3)

¹⁹¹ Where $F_{\text{vdw}}^{\text{max}}$ is the maximum van der Waals force magnitude occuring when $s = s_{\text{min}}^{R}$ (the ¹⁹² minimum separation distance for a particle at its real stiffness). This was varied three orders ¹⁹³ of magnitude, Bo = 10, 100, 1000 which was sufficient variation to interpret cohesive differ-¹⁹⁴ ences. This magnitude of variation was chosen as it showed changes in deposition without ¹⁹⁵ running a large amount of simulations at finer *Bo* intervals. This also gave *A* at *Bo* = 1000 ¹⁹⁶ of the same order of magnitude ($A = 10^{-20}$ J) to drug particles in the inhaler propellant ¹⁹⁷ HFA-227 (Engstrom et al., 2009).

Further complexities arise when considering particle-wall interactions. This is widely treated as a fully plastic collision due to the presence of a respiratory mucus layer (Miyawaki et al., 2012; Zhang et al., 2018; Chen et al., 2012; Naseri et al., 2017). This may occur due to lubrication interactions, which have been experimentally shown to damp collision forces (Legendre et al., 2005) due to the formation of a thin interfacial film during contact. This relation has been shown to follow the expression

$$e_{iw} = \frac{v_R}{v_C} = \exp\left(-\frac{35}{St_{coll}}\right),\tag{4}$$

for solid particles (Legendre et al., 2005). Where subscript $_R$ and $_C$ are the rebound and precollision velocities, respectively, v_T is the terminal velocity of the particle, before it slows

due to interaction with the wall and $St_{coll} = (\rho_p + \rho_f)d_p v_T / 9\mu_f$ (Legendre et al., 2006). 206 e follows a sigmoid trend when plotted against St_{coll} , with $St_{coll} < 10$ creating a plastic 207 collision similar to that approximated in modelling of particle-mucus layer interactions. We 208 implemented this relationship to model particle-wall contact force, then when later deleting 209 or freezing deposited particles, use it to determine the cutoff. We use this to model particle-210 mucus layer collision instead of the typical 'sticking' condition (Miyawaki et al., 2012; Zhang 211 et al., 2018; Chen et al., 2012; Naseri et al., 2017). This allows potential for particle rebound 212 after impacting the wall. Therefore, as the particle-wall interaction is better represented, 213 deposition is not over-estimated. 214

215 2.3. Simulation configuration

216 2.3.1. Single-phase validation

We first verified the fluid phase by qualitative comparison to a published experimental 217 study (Banko et al., 2015). The study observed water flow in a 3D printed hollow cast of 218 an adult male patient's airways (Figure 1a) at a Reynolds number representative of heavy 219 breathing ($Re_{inlet} = \rho_f UD_{inlet}/\mu_f = 3600$ corresponding to Q = 1 L/s). Water flow was 220 simulated to first replicate the experiment before advancing to a simulation of airflow to 221 show independence of the fluid simulated when velocity is scaled by its Re. Water was simu-222 lated using OpenFOAM solver pimpleFoam, then when simulating air we used the CFDEM 223 solver with no particles. We gauged mesh sensitivity by simulating two uniform, hexahedral 224 meshes (5 \times 10⁵ and 10⁶ cells). As interaction between the gas and particle phases (namely, 225 drag) is dependent on the size of Δ relative to d_p , we made our fine mesh cell size $\Delta = 50d_p$ 226 to minimise drag overestimation. This is of the same order of magnitude as coarse-fluid grid 227 simulations performed by Radl and Sundaresan (2014). We kept grid size consistent with 228 our first particle size tested (at $d_p = 10 \,\mu\text{m}$, $\Delta = 500 \,\mu\text{m}$) throughout the study to minimise 229 excessive computation time when later reducing particle size. 230

As upstream fluctuations in the experimental apparatus necessitate a turbulent inlet (Sagaut, 2006), we implemented a boundary condition which adds random components to the flow. This was used with an inflow velocity of $u_{water} = 0.167 \text{ m/s}$ and $u_{air} = 2.677 \text{ m/s}$, with a no-slip condition at the wall. Outlets had a uniform, fixed pressure applied to each bronchi. Although not truly representative of outflow conditions within the lung, a uniform outlet condition has been shown to be acceptable when the bronchi are extended a few diame-

ters in the axial direction to eliminate secondary flow effects (Zhang et al., 2012). This has
been shown to resemble more advanced outlet conditions which consider compliance of the
lung (Ma and Lutchen, 2006).

240 2.3.2. Aerosol transport modelling

In multiphase simulations we coupled the single-phase approach above to the DEM 241 solver to track monodisperse particles of $d_p = 10$ and $4 \mu m$. We began with $10 \mu m$, which are 242 on the upper end of those used in metered-dose inhaler research (Kleinstreuer and Zhang, 243 2010; Watanabe and Watanabe, 2019), to allow faster simulations at this stage to observe 244 variation between patients. This is as timestep size and number of particles (for a desired 245 mass of drug) are dependent upon particle diameter. Particles are classed as deposited and 246 deleted from the system when impacting the wall with low inertia (St_{coll} < 20 Legendre 247 et al. (2005)). As CT scan resolution only permitted segmentation to approximately the sixth 248 bifurcation level (Figure 1), particles reaching the end of the bronchial path were classified 249 as reaching the distal airways and deleted. As we this only model a limited amount of bifur-250 cation levels (between four to six), this is a coarse approximation of downstream behaviour 251 and dosage reaching the small airways. 252

The dosage was released over a period of t = 0.1 s (Ju et al., 2010). The particle motion 253 was discretised in time based on calculation of the collision time of the particles, t_{DEM} = 254 $\pi (2k_n/m - \gamma_n^2/4)^{-1/2}/7$ (Gu et al., 2016*a*). The van der Waals stiffness scaling (Gu et al., 255 2016*a*) was set to $A^S = A^R (k_S/k_R)^{1/2} = A^R/31.6$. Particle lubrication force was modelled 256 using mucus layer viscosity ranging from $\mu_{mucus} = 0.026 - 0.05 \,\text{Pa} \cdot \text{s}$ dependent on dis-257 ease (Rubin, 2007) and a density of $\rho_{mucus} = 1000 \text{ kg/m}^3$ as it is largely made up of water in 258 the upper airways (Olsson et al., 2011). Parameters used are summarised in Table 2. Simu-259 lations were performed on high-performance computers ROCKS of Heriot-Watt and EDDIE 260 of the University of Edinburgh high-performance computers using 28 – 64 CPU cores. 261

Once the optimal parameters were determined, a time-varying inlet condition was implemented to represent a real breathing cycle (Figure 2). For this we used data provided by Colasanti et al. (2004) whom analysed the breathing profile of patients suffering from COPD and cystic fibrosis shortly after an exacerbation. This was also compared to a healthy inhalation profile. To compare the effect of inhalation waveform, the healthy patient was sim-

Table 2: Parameters used in simulations, as well as dimensionless quantities varied. Three separate volume
fractions were used to observe sensitivity to the number of dosage simulated. Three Bond numbers were
simulated to determine the effect of van der Waals forces. Finally, particle-wall lubrication forces were included
by comparing a collision with fixed e and one dependent on St_{coll} .

Parameter	Value	Source	
$\rho_g/\text{kg/m}^3$	1.2	Robinson et al. (2007)	
$\mu_g/Pa \cdot s$	$1.8 imes10^{-5}$		
$d_p^{o}/\mu m$	10, 4, 2	Kleinstreuer and Zhang (2010)	
$\rho_p/\text{kg/m}^3$	1207	Mexichem (n.d.)	
$v_{p,in}/m/s$	30	Newman (2005)	
$k_S/N/m$	100	Gu et al. (2016 <i>a</i>)	
k_R/k_S	1000	Chen et al. (2012)	
μ_p	0.5	Gu et al. (2019)	
e _{ij}	0.9	Gu et al. (2019)	
e _{iw}	$0.9, e_{iw}(St_{coll})$	Legendre et al. (2005)	
Characteristic Quantities	Value (corresponding physical quantities)		
$\phi_{\rm avg}$	$7.4 \times 10^{-8}, 7.4 \times 10^{-7}, 3.7 \times 10^{-6}$		
	$(N_p = 20 imes 10^3, 200 imes 10^3, 10^6)$		
St	0.5		
Re_p	18.5		
Re _{inlet}	3600		
Bo_p	10, 100, 1000		
	$(A^{R}(J) = 1.5 \times 10^{-22}, 1.5 \times 10^{-21}, 1.5 \times 10^{-20})$		

ulated using both the healthy and exacerbation profile presented by Colasanti et al. (2004). 267 The two diseased patients were then simulated under the exacerbation inhalation profile. To 268 evaluate the effect of the missing throat and mouth of the cystic fibrosis patient, we model 269 this patient using the mouth and throat of the healthy and cancer patient. The magnitude 270 of the child's inhalation velocity was lowered by half, based on inhalation velocities used 271 in a similar study (Longest et al., 2006). Following this we focus on the two patients of 272 main interest, the child cystic fibrosis patient and the healthy adult. We compare the effect 273 of reducing particle size from $10 \,\mu\text{m}$ to $4 \,\mu\text{m}$, and alternating the healthy and exacerbation 274 breathing profile. 275

276 2.4. Deposition assessment

In all of these cases particle deposition was analysed by regional groupings of the mouth, throat, trachea, main bronchus and bronchi within each lobe of the lung (as used by Asgharian et al. (2001) and van Holsbeke et al. (2018)). We also provided results grouped into external airways (mouth to end of first branch), and internal airways (airways within the



Figure 2: Breathing profiles for healthy and diseased patients used in this study (Colasanti et al., 2004). Positive flow rate represents inhalation and negative represents exhalation. A standard sinusoidal breathing profile is shown for comparison. Differences between healthy and simplified breathing conditions are minor, but the exacerbation profile reaches a higher peak inhalation at a faster rate.

²⁸¹ lungs). We use this to evaluate preferential deposition within airways' different regions.

In contrast to the fully plastic particle-wall condition used in literature, our particles may rebound as we resolve collisions over multiple timesteps. We classed particles that had low inertia prior to impacting the wall as deposited. This inertia was based on Equation (4). We compared results where these particles were kept active in the domain to interact with floating particles, or where we simply deleted them. The difference in these was found to be minimal (under 5% in all regions). Therefore we opted to delete them due to superior computational efficiency (reached 0.1 s physical time in 30% faster clock time).

²⁸⁹ Due to the particle's ability to slide along the wall in our parameter study simulations, ²⁹⁰ when stuck it would not be completely stationary. To extract particles on the wall for com-²⁹¹ parison to our sticking condition, deposition was defined when the particle velocity was ²⁹² sufficiently below that of the free-stream (v = 0.01 m/s, 900 times less than gas velocity ²⁹³ in the throat). This velocity cutoff was found through observed comparison of velocities ²⁹⁴ of slowly floating and deposited sliding particles. Particles that were below this threshold ²⁹⁵ were classed as deposited deleted during post-processing.

Due to the locally-acting nature of metered-dose inhalers (Lu et al., 2015), it is important to understand therapeutic distribution and dosage experienced by the patient based on deposition concentration (Solomon et al., 2012). We interpreted this through the dosimetry

²⁹⁹ measure of deposition enhancement factor (DEF) (Balashazy et al., 1999; Longest et al., 2006). ³⁰⁰ We calculate this using the number of particles deposited within a fixed distance (1 mm, area ³⁰¹ $A_{conc} = \pi (1 \text{ mm})^2$) of the central point of each wall face. This distance was based on that ³⁰² used by Dong et al. (2019). Other studies have used much narrower radii (Longest et al., ³⁰³ 2006; Xi et al., 2012), but using this wider radius can account for particle translocation during ³⁰⁴ the time between deposition and absorption. This is made relative to the global deposition ³⁰⁵ by

$$DEF = \frac{Deposition concentration within A_{conc} / A_{conc}}{Total deposited particles / Total airway surface area}.$$
 (5)

We use this instead of the sum of the deposition efficiencies as the defined areas may overlap, and this therefore prevents particles being counted multiple times towards the global average.

309 3. Results

310 3.1. Single-phase validation

The sensitivity of aerosol particles to changing flow structures (as St < 1) makes single-311 phase flowfield validation crucial before considering particles. Turbulence induced in the 312 upper airways is the foundation of the flow structure, creating secondary flows which are 313 responsible for deposition in the trachea (Jin et al., 2007; Kleinstreuer and Zhang, 2010). 314 Therefore, the upper airways are a suitable region for the validation (Figure 3). All results 315 have been normalised by the mean velocity in the trachea ($V_{T,water} = 0.22 \text{ m/s}$ and $V_{T,air} =$ 316 3.51 m/s). The strong jet of flow formed at the throat matches the experimental study well 317 in magnitude and structure, capturing the recirculation zones as the throat expands well. 318 Banko et al. (2015) gave the bulk (area-averaged) velocity U relative to V_T as 1.73 in the 319 glottis, compared to our value of 1.77, producing a 2.3% relative error. 320

The resemblance in flow structure continues in the lower airways, from both coronal and axial views as given in Figure 4 (see Banko et al. (2015) for further comparison). The slight separation seen at the left bronchus (right side of (a)) agrees well with the experimental data. Contours in the axial region (shown in (b)) agree well in shape, accurately capturing recirculation and asymmetrical flow. However, velocity vectors shown in C-C' and D-D' differ from the published results. This likely stems from differences in time-averaging of such a sensitive parameter in highly unsteady flow. Vectors in B-B' and E-E' match the experimen-



Figure 3: Comparison of single-phase flow in the upper airways to demonstrate mesh independence and independence of water and gas simulations at equal Reynolds numbers. (a) Location of shown contour (red) in domain (Banko et al., 2015, Figure 5), with arrows indicating direction of view for comparison of the normalised velocity magnitude contours of: (b) experimental obtained water flow (Banko et al., 2015, Figure 5), and numerically obtained water flow on a (c) moderate grid density and (d) fine grid. (e) Numerically obtained airflow on a fine grid.



Figure 4: Time-averaged water velocity field at the first bifurcation, structured the same as presented in experimental study (Banko et al., 2015, Figure 9) for ease of comparison. (a) Normalised velocity magnitude at the first bifurcation from the coronal view, and (b) the velocity magnitude normal to the flow at various axial cuts shown in (a).

tal data well. Qualitatively comparing numerical and experimental velocity fields (Banko 328 et al., 2015) verifies that the single-phase flow configuration is suitable to capture the flow 329 patterns present. To quantitatively validate the solver, we compare the relative bulk velocity 330 (U/V_T) . Banko et al. (2015) gave this as 1.03 in the trachea, matching our solver exactly. In 331 the left main bronchus, we had a value of 0.67, differing from the experimental results of 332 0.70 by 4.3%. In the right bronchus the numerical and experimental $U/V_T = 0.88$ and 0.87, 333 respectively (relative error 1.2%). These relative bulk velocity comparisons at key cross sec-334 tions of the airway validate that our solver can reproduce the *in vitro* respiratory velocimetry 335 measurements of Banko et al. (2015) to an error below 5%. 336

337 3.2. Effect of parameter variations

To model inhaler inhalation the simulation's sensitivity to the dosage simulated, van der Waals forces and particle-wall lubrication forces were evaluated. The influence of each of these were examined by their influence on dosage deposition.

As physical parameters were varied, one can observe that deposition distinctions are 341 mostly minor, as deposition changes across each lobe were all under 1.5% of the total dosage 342 (Figure 5). When increasing the number of particles the only change came at $N_p = 1,000,000$ 343 (Figure 5c), as the throat deposition rose by 2%, in all other regions the difference was less 344 than 1%. For this reason 200,000 particles was chosen for the remaining simulations to 345 reduce run times. Although we have purposely underestimated N_p , the number of parti-346 cles should not be chosen arbitrarily. Instead the sensitivity of the model to this parameter 347 should be included as an early simulation in all studies where the true payload cannot be 348 simulated. When including particle cohesion and particle-wall lubrication (Figure 5h,i), de-349 position in the throat due to particle-wall lubrication forces rose by 13% of the total dosage. 350 This effect is reduced by 4% when modelling van der Waals forces, likely explained by the 351 agglomeration of particles providing additional inertia (increasing *St*_{coll}), thus reducing the 352 energy lost due to lubrication. This also explains why minimal changes are observed in 353 Figure 5(d - f). 354

The parameters taken forward to evaluate deposition variance in the diseased patients were: a dosage of 0.126 µg ($N_p = 200,000$ at $d_p = 10$ µm), a Bond number of 1000, and particle-wall lubrication forces. Time-varying breathing profiles were also applied (Figure 2). Although particle count is underestimated, the error is within 5%, for a computation time reduction of 62% ($N_p = 200,000$ took three weeks, whereas $N_p = 1,000,000$ took eight). These parameters were considered to model the particle behaviour accurately, with a small sacrifice made to reduce computational cost.

362 3.3. Inter-patient variation

Due to the dominance of upper airway deposition, it is difficult to visualise differences in central airway deposition. When viewing deposition as a logarithm the behaviour in the lobes can be analysed with greater ease (Figure 6). Across the five simulations the dosage was mainly deposited in the external airways (Figure 6), deposition here was always greater



Figure 5: Dosage deposited within each region of the airways with time, for the parameter variations given in Table 2. (a, b, c) Compares deposition with simulation of various particle numbers. Remaining rows present results using $N_p = 200,000$. (d, e, f) Shows deposition with variation of the van der Waals force in relation to the dimensionless quantity *Bo*. (g, h, i) Compares deposition with inclusion of lubrication forces and van der Waals particle-particle interactions. Each line is representative of an airway region, corresponding to the coloured airway included in the left-most plot of each row. An additional grey, dashed line is included to show the rate at which particles enter the system from the inhaler.

than half of the payload. Given the size of the particles compared to the distribution used in inhalers, a large deposit here was expected. For the most constricted external airways (Figure 6c,d) the deposition fraction was 0.95 and 0.85, respectively. The lower throat deposit in the child, despite using a scaled replica of the cancer patient's airways above the trachea, indicating the weaker inhalation is beneficial here. The cystic fibrosis patients' deposition dropped by 13.4% in the trachea (relative to total dose) when using the dilated airway, however deposition rises elsewhere meant the total drop was 12.5% (Figure 6d, e). There is an

external airway deposition rise of 1.9, 1.7 and 1.5 times when comparing the healthy patient with exacerbation breathing against the cancer and cystic fibrosis patients (constricted and dilated), respectively. Considering only 'stuck' particles (non 'exiting' particles), the ratio of external to internal airway deposition ranged from 3 to 61.

Both patients with the constricted throat (Figure 1ii, iii) received below 5% of the dosage 378 to the deep airways (Figure 7). When replacing the constricted throat with the dilated throat 379 in the cystic fibrosis patient, dosage in this region increased to 14% of the total payload. 380 In the two healthy patient simulations this number increased to 31 and 19% for healthy 381 and the exacerbation inhalation. Lobar distribution of these particles for healthy and the 382 exacerbation inhalation was mainly directed to the lower lobes (67 and 56% of total exited) 383 and the left:right lung ratio of dosage reaching the distal airways was 1.1 and 1.6. Left:right 384 deep lung ratio was 0.2 for the lung cancer patient, 0.3 for cystic fibrosis patient (i) and 385 0.91 for cystic fibrosis patient (ii). This shows a noticeable difference between healthy and 386 diseased airways. 387

388 3.4. Particle size reduction

As improvements to device efficiency are generally realised through the patient's breath-389 ing and the particle sizes, we applied these to the two main cases of interest (the healthy 390 adult and cystic fibrosis child patients). Particle size was reduced to 4 µm using the exacer-391 bation profile. We applied the healthy breathing profile to both patients with 10 µm particles. 392 Deposition in the external airways gives no clear trend of improvement (Figure 8). We see 393 the change in breathing yields a deposition reduction of 43% for the cystic fibrosis patient, 394 but a rise of 4% in the healthy patient. Similarly reducing the particle size yields a deposition 395 increase of 3% for the cystic fibrosis patient, but a deposition reduction of 56%. This reduc-396 tion does not appear to impact the dosage reaching the deep lung, as during exacerbating 397 breathing this value does not differ by more than 0.5% for 10 and 4 µm particles. 398

399 3.5. Dosimetry assessment

In all simulations, hotspots were observed at the back of the mouth, throat, upper trachea, first and second bifurcations (Figure 9). The healthy patient's drug deposits were limited to this region under normal breathing (Figure 9a,e), but during an exacerbation the particles form a uniform coating across the airways with a DEF value of 1–5 in the bronchi,



Figure 6: Comparison of regional deposited particles in three diseased model airways throughout a breathing cycle (Figure 2). Deposition is shown on a log scale to allow closer analysis of lobar deposits. Again time has been normalised and patient illnesses described each plot. Line colours correspond to region in the coloured, generic airway tree on the left. Rate of particle injection to the domain given by the grey, dashed line. Distribution of exited particles, not considered in this graph, are shown in Figure 7.



Figure 7: Percentage of dosage progressing to the lower airways of each patient, shown for each lobe of the lung. This represents the particles which have 'exited' from the patients shown in Figure 6. Overlapping points have been offset to in the *x* axis to aid visualisation.

20 at the first bifurcation, and 20–250 in regions of the throat. This is much larger than under 404 healthy breathing, where the in the throat the range is 10–100, and 10 at the first bifurcation. 405 We see less intense hotspots in bronchi of the two diseased patients. At the first bifurcation, 406 DEF = 0.2 and 5 for the cancer and cystic fibrosis patients (i), respectively. The dose is con-407 centrated in the throat at the narrow throat, where in both patients the values range from 20 408 to 120. Trachea deposition is favoured to the front as the mean DEF here is 1, and 1.6 for the 409 cancer and cystic fibrosis patient, respectively (Figure 9c,d). This is much smaller (the order 410 of 10^{-3}) at the rear of the trachea in these patients (Figure 9g,h). The cystic fibrosis patient 411 with the constricted and dilated throat shows similar local behaviour below the carina, as 412 there are sparse patches of drug deposits. These are narrow and more intense in the cystic 413 fibrosis patient with the dilated throat (DEF = 1 to 13 in the first few bifurcations, decreasing 414 to 0.1 to 1.5 in the distal bronchi), but appear the slightly larger in area in the cystic fibrosis 415 patient with the constricted throat. Mean DEF at the first bifurcation is 5.5 (Figure 9e), only 416 0.5 higher than the same patient with the constricted upper trachea (Figure 9d). 417

418 **4. Discussion**

In this study we aimed to evaluate deposition in patient-specific models during exacerbating breathing, compared to during healthy breathing. This allowed the investigation to



Figure 8: Delivery changes in (a) external (mouth to first bifurcation) and (b) deep airways in two cases of main interest as inhaler particle size and breathing profile change. Line style is consistent with all variations in the patient. Black, blue and red lines denote exacerbating breathing with 10 µm, healthy breathing with the same particle size, and exacerbating breathing with 4 µm particles.

consider short-acting bronchodilators ('reliever' inhalers). By investigating this in a small, 421 diverse patient group we found patient-specific domains to be a necessity in future studies. 422 Results showed less drug reaching the deep lung during an exacerbation, but the main dif-423 ferences came in the patients with distinct changes in upper airways (shape and size). The 424 increased upper airway deposition is attributed to the greater constriction and complexity 425 here, particularly in the cancer patient (Figure 1b). From the brief parameter study, this ap-426 peared to overrule the effect of particle-particle interactions such as collisions. This shows 427 that patient-specificity in the upper airways is crucial for accurate deposition prediction. 428



Figure 9: Concentration of drug deposits in each model, normalised by total global deposition (DEF, Equation (5)). Hotspots visualised from the (a-e) front and (f-j) rear of each model. The maximum value (DEF = 350), describes an area with a drug concentration 350 times greater than the mean DEF of 1. Dosage is most concentrated in the throat as shown in Figure 6.

We have seen unexpected reactions from some patients to reducing particle size and applying the healthy breathing profile (Figure 8). Typically smaller particles and steadier breathing reduce mouth and throat deposition as shown *in vivo* by Usmani et al. (2005). This further emphasises the need for the use of patient-specific domains, as we have seen a small rise in external airway deposition when reducing particle size from 10 to 4 µm for the cystic fibrosis patient. Conversely, for the healthy patient we see a external airway de-

position rise of over double with this change in particle sizes. This agrees with reduced 435 deposition in central airways for smaller particles (Usmani et al., 2005). Similar trends were 436 seen when comparing breathing profiles in the healthy patient, as there was a small rise in 437 external airway deposition with the healthier breathing profile (but also a rise in deep lung 438 dosage). A potential cause for these abnormal observations could be the unpredictability 439 of the mesoscale interactions such as particle collisions, van der Waals forces and particle-440 wall lubrication, and their change with the changing flow structures in different patient 441 airways (Figure 5). In contrast to other patient-specific deposition studies that did not con-442 sider particle-particle interactions (Choi et al., 2018; Koullapis et al., 2018; Poorbahrami and 443 Oakes, 2019), we chose to use CFD-DEM with particle-particle interactions. This was as 444 cohesive van der Waals forces have been known to influence the transport of micro-scale 445 particles (Gu et al., 2016a). Soft-sphere (treating particles as deformable) deposition studies 446 have been implemented before but only to observe dynamics in simplified airways (Chen 447 et al., 2012; Wang et al., 2017). This allows understanding of particle dynamics in a fixed 448 system. However, our results in Figure 6 have shown, there are changes in flow dynamics 449 across different patients which may alter the influence of particle interactions. For example, 450 in narrow airways the particle concentration will be denser than in a patient with wider 451 airways and cause more cohesion. This is a speculative explanation as our results in Fig-452 ure 5 show small variation with cohesive forces. The minor influence of cohesion in our 453 simulations is aligned with the small localised changes shown by Wang et al. (2017) when 454 modelling cohesion. As suggested by Islam et al. (2020) the effect of particle-particle interac-455 tions should be investigated across many cases to understand their influence on respiratory 456 drug delivery, but our study has provided a first step towards this. To use modelling to in-457 form patient treatments an understanding of different particle forces and their change with 458 drug properties is important. 459

Dosimetry analysis across the patients show noticeable differences in deposition in the trachea (Figure 9), attributable to transitioning from the fast-flowing, constricted throat to the expanding and curved trachea, of the cystic fibrosis and cancer patients. This agrees with single-phase simulations of Wei et al. (2017) that found flow to vary with orientation, as well as Bates et al. (2016) who showed the effect of pathological trachea curvature on gas pressure

and energy loss. Also the change in relative orientation of the trachea to gravity present an 465 additional factor to deposition changes. We also see a more uniform coating in the central 466 airways of the healthy patient during exacerbating breathing, compared to normal breath-467 ing. As drug concentration across the airway surface is important in its dissolution into the 468 tissue (Solomon et al., 2012), this provides a deeper understanding of the drug's absorption 469 than a simple deposition analysis. These results could be input to a model of the particle's 470 interaction with the tissue at smaller scales, as has been done by Olsson and Bäckman (2018) 471 using 1D deposition data. Using CPFD for this could further inform clinicians in comparing 472 potential treatment and delivery techniques for a patient. 473

When observing intra-patient drug delivery, the results presented show an uneven dis-474 tribution across the lobes. There is a clear favour in transport to the lower lobes of the lung 475 (Figure 7). This is similar to observations made by Lambert et al. (2011). Deposition is dom-476 inant in the right lung in the diseased patients, agreeing with experimental data (Usmani 477 et al., 2005; De Backer et al., 2008). Patient-specific models could be used to attain a bal-478 anced dosage distribution, or target a specific region. This could allow for improved symp-479 tom relief through inhaler design informed by knowledge of regions sensitive to local in-480 flammation (Barbu et al., 2011), allowing for more efficient devices. Additionally, cancerous 481 regions of the lung could be targetted for chemotherapy using nebulisers (Tatsumura et al., 482 1993; Kleinstreuer and Zhang, 2003; Kleinstreuer et al., 2007). Clinicians could therefore pre-483 dict and tailor the chemotheraputic agent delivery through patient-specific CPFD models 484 to minimise radiation reaching undesired areas of the lung. As course of chemotherapeu-485 tic treatment is given over a large period of time (given in three week intervals by Wittgen 486 et al. (2007)), this fits well with a high accuracy, time-consuming modelling method such as 487 CFD-DEM. 488

Interestingly, the only lobar distribution changes in deep lung delivery occurred in the healthy patient as the left upper lobe received less medication with healthier breathing (Figure 7). Apart from this, the quantity of the dosage reaching distal lung regions increased with the longer, slower inhalation, but the distribution among lobes remained similar. This was also true for the cystic fibrosis patient (Figure 8b). This finding is beneficial as it suggests the drug's behaviour does not differ significantly in extreme circumstances. However

23

this is limited by a lack of knowledge of ventilation changes during exacerbations. Such 495 information can be obtained by imaging combined with respiratory tests during healthy 496 conditions (De Backer et al., 2010, 2014). To model deposition during an exacerbation, pa-497 rameters usually obtained from imaging may need to be approximated in future studies. 498 However, CPFD can be used to model exacerbations and avoid any dangerous experiments. 499 Limitations of this study included the absence of imaging data available for the throat 500 and mouth of the child, meaning this region was taken from the other patients and scaled. 501 This of course limits the specificity of the main deposition site. However by simulating with 502 the two available throat geometries merged to the child's trachea we can see that the deposi-503 tion in this region itself is unaffected (only changing 1%). The only differences are observed 504 downstream in trachea deposition (Figure 6) and deep lung dosage (Figure 7). Therefore, to 505 neglect this region completely would harm the accuracy of the results downstream as flow 506 generated in the upper airways heavily impacts downstream behaviour of both the gas and 507 the particles (Figure 4). However, adding this region from adult patient to a child does take 508 into account the maturational effects of adolescence on the airway, which may impact depo-509 sition here. In future studies, images containing the mouth and throat are needed to ensure 510 this important section is patient-specific. 511

An additional limitation is that patients lying down in scans may have slightly different airway shape and orientation when standing or sitting upright (Jan et al., 1994), as is a typical posture when taking inhalers. If using image-based CPFD to recommend treatments, the patient images should be consistent with their typical posture when using their treatment where possible.

⁵¹⁷Only modelling the small number of airway bifurcation levels visible in the CT scan lim-⁵¹⁸its the model to only providing deposition information about the upper and central airways. ⁵¹⁹To understand drug delivery in the smaller more distal airways the particles 'exiting' from ⁵²⁰our model's outlets could be coupled to analytical 1D models (Koullapis et al., 2019). These ⁵²¹models predict deposition based on particle size, estimated airway length and diameter, ⁵²²and flow rate. This would allow for a coarse prediction of drug delivery and efficacy in the ⁵²³targeted small airways.

524

Assumptions included the simulation of a uniform particle distribution. A uniform dis-

tribution is commonly used to research aerosol physics experimentally (Usmani et al., 2005, 525 2003), although does not directly represent the varying size distribution of inhaler parti-526 cles (Dolovich, 1991). This is due to the small range of particle sizes (geometric standard 527 deviation below two (Mitchell et al., 2003)) in a real device, meaning St < 1 in all cases, 528 therefore the particles will exhibit high sensitivity to flow changes in both polydisperse and 529 monodisperse flows. Deposition results should not be appreciably different as no transport 530 characteristics are changed by this approximation. This allowed patient morphology differ-531 ences to be evaluated in a simpler manner, without sacrificing accuracy. 532

A final modelling limitation is the softening of the particles. Particle softening is stan-533 dard in DEM simulations to permit a larger DEM timestep as the particle's collision happens 534 over a longer period due to a lower stiffness. We mitigate an impact of increased van der 535 Waals forces by including the cohesion model of Gu et al. (2016a). This model makes co-536 hesive particle flows independent of their stiffness, and therefore increases our simulation 537 timestep from $t_{\text{DEM}} = 0.8$ ns to 25 ns. This reduction of real particle stiffness (k_R) to a softer 538 stiffness (k_s) has been shown to have negligible effect on fluid hydrodynamics and particle 539 cohesion (Gu et al., 2016a; Ozel et al., 2017). The use of this model therefore makes the effect 540 of softening particles negligible. This allows us to use DEM to model inhaler particle-particle 541 and particle-wall interactions with feasible computation times. 542

543 5. Conclusion

We have performed patient-specific inhaler deposition simulations across three diverse patients during exacerbating inhalation conditions. This has been compared to a healthy control patient and using a healthy and exacerbating breathing profile, showing that during an exacerbation less of the drug reaches the deep lung.

⁵⁴⁸ We have applied common means of improving drug delivery such as reduced particle ⁵⁴⁹ size and a slower, steadier inhalation. Neither of these showed a common reduction in ex-⁵⁵⁰ ternal airway deposition. This also shows the shortcomings in treating diverse populations ⁵⁵¹ with generic treatments. This demonstrates the need for personalised airways in respiratory ⁵⁵² CPFD studies, including the mouth and throat.

In the healthy patient the distribution of particles behaves as expected. This was fairly balanced across each lung, and primarily in the lower lobes of the lung (due to particle inertia). However we found particle distribution to be far less balanced in the diseased patients, as left to right lung deposition ratio was as low as 0.2 in their worst case. We
predict this heterogeneity may be furthered upon inclusion of ventilation differences in the
study to follow—particularly if patients studied suffer from issues such as mucus plugging
or collapsed lung regions.

560 Acknowledgements

For their early involvement and insight into the issue faced by patients, the authors
 would like to thank Elisabeth Ehrlich and Olivia Fulton. Also Carol Porteous (Patient Public
 Involvement Advisor) who arranged our contact.

The authors thank Prof. Vicki Stone from Heriot-Watt University for fruitful discussions. The authors also thank Dr Filippo Coletti from University of Minnesota for providing the surface file of the healthy patient's segmented airways that enabled our model validation and was used to compare deposition across the patients. AO thanks Prof. Sankaran Sundaresan from Princeton University for his support and fruitful discussions. JW thanks Dr Rudolf Hellmuth from Vascular Flow Technologies for fruitful discussions.

JW was funded by an Institution of Mechanical Engineers Postgraduate Masters Scholarship 2018, a Scottish Funding Council Masters fee scholarship 2018, and a Carnegie-Trust for the Universities of Scotland PhD scholarship 2019.

⁵⁷³ Appendix A. Gas and solid-phase modelling

Simulations in this study solve fluid transport through the respiratory system on a Eulerian grid with Lagrangian particle tracking using the discrete element method (DEM). We solve the volume filtered mass (A.1) and momentum (A.2) continuity equations at each finite-volume cell. Here they are presented in terms of the volume filtered variables, accounting for particle interactions as derived by Anderson and Jackson (1967) and Capecelatro and Desjardins (2013), with overbars denoting filtered terms and bold, lower- and uppercase characters describing vectors and second order tensors, respectively,

$$\frac{\partial}{\partial t}(1-\phi) + \nabla \cdot \left[(1-\phi)\bar{u}\right] = 0, \tag{A.1}$$

$$\rho_f(1-\phi)\left(\frac{\partial \bar{u}}{\partial t}+\bar{u}\cdot\nabla\bar{u}\right) = \nabla\cdot(\bar{\tau}-R_u)+\Phi_d+\rho_f(1-\phi)g.$$
(A.2)

Where subscript t is time, \bar{u} is the filtered local velocity vector, \bar{p} is the filtered local fluid-581 pressure, ρ_f is the fluid density, ϕ is the particle volume fraction, g is gravity (assumed con-582 stantly acting downwards at 9.81 N/kg), the force caused by interaction with the discrete 583 phase is $-\Phi_d$, R_u is the sub-grid stress from filtering, modelled using a dynamic Smagorin-584 sky model (described in Section 2.2). $\bar{\tau}$ is the filtered fluid stress tensor, composed of the 585 fluid pressure gradient ($\nabla \bar{p}$), the deviatoric viscous stress tensor (labelled below), and an 586 additional term arising from filtering of sub-grid velocity fluctuations (R_{μ}) (Capecelatro and 587 Desjardins, 2013) 588

$$\overline{\tau} = \nabla \overline{p} + \underbrace{\mu_f \left[\nabla \overline{u} + \nabla \overline{u}^T - \frac{2}{3} (\nabla \cdot \overline{u}) I \right]}_{deviatoric \ viscous \ stress \ tensor} + R_\mu$$
(A.3)

Where I is an identity tensor and R_{μ} is the term arising from filtering velocity gradients. In 589 this study we dismissed R_{μ} to be included in a later study, and the deviatoric part of the 590 stress tensor due to its minor influence on gas-solid flows in comparison to R_u (Agrawal 591 et al., 2001). Φ_d is dependent on the interaction force between particles and fluid $(f_{f \rightarrow p,i})$ of 592 all particles within a cell volume (\mathcal{V}_{cell}) by, $\mathbf{\Phi}_d = -\frac{\sum_{i=1}^{N_p} f_{f \to p,i}}{\mathcal{V}_{cell}}$ (Anderson and Jackson, 1967; 593 Capecelatro and Desjardins, 2013; Ozel et al., 2017). For a particle *i*, this is related to the 594 filtered fluid stresses and the particle's drag by $f_{f \to p,i} = \mathcal{V}_i \nabla \cdot \bar{\tau} + f_{d,i'}$ where $f_{d,i}$ is the drag 595 force, taken from Beetstra et al. (2007). 596

Newton's equations of motion are used to track particle linear motion (A.4) and angular
 motion (A.5) (Cundall and Strack, 1979; Capecelatro and Desjardins, 2013), by

$$m_i \frac{dv_i}{dt} = \sum_j (f_{c,ij}^n + f_{c,ij}^t) + \sum_w (f_{c,iw}^n + f_{c,iw}^t) + \sum_k f_{v,ik} + f_{f \to p,i} + m_i g$$
(A.4)

$$I_i \frac{d\omega_i}{dt} = \sum_j (\mathbf{n} \times f_{c,ij}^t). \tag{A.5}$$

⁵⁹⁹ Where m_i is the mass of a particle, *i*, *v* and ω are the particle's translational and angular ⁶⁰⁰ velocity, respectively, f_c is the contact force from a particle-particle collision (subscript $_{ij}$), ⁶⁰¹ and particle-wall collision (subscript $_{iw}$), in the normal and tangential directions shown by ⁶⁰² sub or superscript *n* and *t*, respectively. van der Waals forces are shown with $_v$. Angular ⁶⁰³ momentum (A.5) from inter-particle collisions depends on outward unit normal vector from ⁶⁰⁴ particle centre to the point of collision, *n*, and the tangential contact force $f_{c,ij}^t$. Particle

contact forces are solved here using a linear spring-dashpot model (Cundall and Strack,
 1979; Capecelatro and Desjardins, 2013),

1

$$f_{c,ij}^n = k_n + \delta_n \boldsymbol{n}_{ij} - \gamma_n \boldsymbol{m}^* \boldsymbol{v}_{ij}^n, \tag{A.6}$$

$$\boldsymbol{f}_{c,ij}^{t} = \begin{cases} k_{t}\boldsymbol{t}_{ij} - \gamma_{t}m^{*}\boldsymbol{v}_{ij}^{t} & \text{for} \quad \left|\boldsymbol{f}_{c,ij}^{t}\right| < \mu_{s} \left|\boldsymbol{f}_{c,ij}^{n}\right|, \\ -\mu_{s} \left|\boldsymbol{f}_{c,ij}^{n}\right| \frac{\boldsymbol{t}_{ij}}{\left|\boldsymbol{t}_{ij}\right|} & \text{for} \quad \left|\boldsymbol{f}_{c,ij}^{t}\right| \ge \mu_{s} \left|\boldsymbol{f}_{c,ij}^{n}\right|. \end{cases}$$
(A.7)

⁶⁰⁷ Where *k*, is the particle's spring constant with $k_t = 2k_n/7$ (Matuttis et al., 2000), δ is the ⁶⁰⁸ particle overlap distance, γ is the viscous damping coefficient. γ_n is calculated from the ⁶⁰⁹ coefficient of restitution $e = \exp(\gamma_n \pi / \sqrt{4k_n/m^* - \gamma_n^2})$ (Gu et al., 2016*b*). $\gamma_t = 2\gamma_n/7$. Effec-⁶¹⁰ tive particle mass is $m^* = m_i m_j / (m_i + m_j)$, in particle-wall collisions $m^* = m_i$, as one radius ⁶¹¹ is assumed infinite (Gu et al., 2016*a*); μ_s is the sliding coefficient; t_{ij} represents the tangential ⁶¹² displacement due to a collision, found from the integral of its velocity component.

613 **References**

- Agrawal, K., Loezos, P. N., Syamlal, M. and Sundaresan, S. (2001), 'The role of meso-scale
 structures in rapid gas–solid flows', *Journal of Fluid Mechanics* 445, 151–185.
- ⁶¹⁶ Anderson, T. B. and Jackson, R. (1967), 'Fluid mechanical description of fluidized beds. equa-
- tions of motion', Industrial & Engineering Chemistry Fundamentals 6(4), 527–539.
- Anjilvel, S. and Asgharian, B. (1995), 'A multiple-path model of particle deposition in the rat
 lung', *Fundamental and Applied Toxicology* 28(1), 41–50.

Asgharian, B., Hofmann, W. and Bergmann, R. (2001), 'Particle deposition in a multiple-path
 model of the human lung', *Aerosol Science & Technology* 34(4), 332–339.

- ⁶²² Aykac, D., Hoffman, E. A., McLennan, G. and Reinhardt, J. M. (2003), 'Segmentation and ⁶²³ analysis of the human airway tree from three-dimensional X-ray CT images', *IEEE trans*-
- actions on medical imaging **22**(8), 940–950.
- ⁶²⁵ Balashazy, I., Hofmann, W. and Heistracher, T. (1999), 'Computation of local enhancement
- factors for the quantification of particle deposition patterns in airway bifurcations', Journal
- of Aerosol Science **30**(2), 185–203.

- Banko, A., Coletti, F., Schiavazzi, D., Elkins, C. and Eaton, J. (2015), 'Three-dimensional
- inspiratory flow in the upper and central human airways', *Experiments in Fluids* 56(6), 117.
- Barbu, C., Iordache, M. and Man, M. (2011), 'Inflammation in COPD: pathogenesis, local
 and systemic effects', *Rom J Morphol Embryol* 52(1), 21–27.
- Bates, A., Cetto, R., Doorly, D., Schroter, R., Tolley, N. and Comerford, A. (2016), 'The ef-
- fects of curvature and constriction on airflow and energy loss in pathological tracheas',
 Respiratory physiology & neurobiology 234, 69–78.
- Beetstra, R., van der Hoef, M. A. and Kuipers, J. (2007), 'Drag force of intermediate reynolds
 number flow past mono-and bidisperse arrays of spheres', *AIChE journal* 53(2), 489–501.
- Behnaz, A. S., Snider, J., Chibuzor, E., Esposito, G., Wilson, E., Yaniv, Z., Cohen, E. and
 Cleary, K. (2010), Quantitative ct for volumetric analysis of medical images: initial results
- ⁶³⁹ for liver tumors, *in* 'Medical Imaging 2010: Image Processing', Vol. 7623, International
- ⁶⁴⁰ Society for Optics and Photonics, p. 76233U.
- ⁶⁴¹ Borghardt, J. M., Weber, B., Staab, A. and Kloft, C. (2015), 'Pharmacometric models for char-⁶⁴² acterizing the pharmacokinetics of orally inhaled drugs', *The AAPS journal* **17**(4), 853–870.
- ⁶⁴³ Capecelatro, J. and Desjardins, O. (2013), 'An euler–lagrange strategy for simulating particle ⁶⁴⁴ laden flows', *Journal of Computational Physics* 238, 1–31.
- ⁶⁴⁵ Chen, X., Zhong, W., Zhou, X., Jin, B. and Sun, B. (2012), 'CFD–DEM simulation of particle
 ⁶⁴⁶ transport and deposition in pulmonary airway', *Powder Technology* 228, 309–318.
- ⁶⁴⁷ Choi, S., Miyawaki, S. and Lin, C.-L. (2018), 'A feasible computational fluid dynamics study
- ⁶⁴⁸ for relationships of structural and functional alterations with particle depositions in severe
- asthmatic lungs', *Computational and mathematical methods in medicine* **2018**.
- ⁶⁵⁰ Clark, A. (1995), 'Medical aerosol inhalers: past, present, and future', *Aerosol science and* ⁶⁵¹ *technology* 22(4), 374–391.
- ⁶⁵² Clark, K., Vendt, B., Smith, K., Freymann, J., Kirby, J., Koppel, P., Moore, S., Phillips, S.,
 ⁶⁵³ Maffitt, D., Pringle, M. et al. (2013), 'The Cancer Imaging Archive (TCIA): maintaining
- and operating a public information repository', *Journal of digital imaging* **26**(6), 1045–1057.

- ⁶⁵⁵ Colasanti, R. L., Morris, M. J., Madgwick, R. G., Sutton, L. and Williams, E. M. (2004), 'Anal-
- ysis of tidal breathing profiles in cystic fibrosis and COPD', *Chest* **125**(3), 901–908.
- ⁶⁵⁷ Cundall, P. A. and Strack, O. D. (1979), 'A discrete numerical model for granular assemblies',
 ⁶⁵⁸ *Geotechnique* 29(1), 47–65.

Darquenne, C., Fleming, J. S., Katz, I., Martin, A. R., Schroeter, J., Usmani, O. S., Venegas, J.
 and Schmid, O. (2016), 'Bridging the gap between science and clinical efficacy: physiology,

⁶⁶¹ imaging, and modeling of aerosols in the lung', *Journal of aerosol medicine and pulmonary* ⁶⁶² *drug delivery* 29(2), 107–126.

⁶⁶³ Das, P., Nof, E., Amirav, I., Kassinos, S. C. and Sznitman, J. (2018), 'Targeting inhaled aerosol

delivery to upper airways in children: Insight from computational fluid dynamics (cfd)',
 PloS one 13(11), e0207711.

De Backer, J., Vos, W., Gorlé, C., Germonpré, P., Partoens, B., Wuyts, F., Parizel, P. M. and
 De Backer, W. (2008), 'Flow analyses in the lower airways: patient-specific model and
 boundary conditions', *Medical engineering & physics* 30(7), 872–879.

De Backer, J., Vos, W., Vinchurkar, S., Van Holsbeke, C., Poli, G., Claes, R., Salgado, R. and
 De Backer, W. (2014), 'The effects of extrafine beclometasone/formoterol (bdp/f) on lung
 function, dyspnea, hyperinflation, and airway geometry in copd patients: novel insight
 using functional respiratory imaging', *Journal of aerosol medicine and pulmonary drug delivery* 27(0), 1–12.

De Backer, J. W., Vos, W. G., Vinchurkar, S. C., Claes, R., Drollmann, A., Wulfrank, D., Parizel,
P. M., Germonpré, P. and De Backer, W. (2010), 'Validation of computational fluid dynamics in ct-based airway models with spect/ct', *Radiology* 257(3), 854–862.

⁶⁷⁷ De Nunzio, G., Tommasi, E., Agrusti, A., Cataldo, R., De Mitri, I., Favetta, M., Maglio, S.,

Massafra, A., Quarta, M., Torsello, M. et al. (2011), 'Automatic lung segmentation in CT

⁶⁷⁹ images with accurate handling of the hilar region', *Journal of digital imaging* **24**(1), 11–27.

⁶⁸⁰ Dockrell, M., Partridge, M. and Valovirta, E. (2007), 'The limitations of severe asthma: the ⁶⁸¹ results of a european survey', *Allergy* **62**(2), 134–141.

- ⁶⁸² Dolovich, M. (1991), 'Measurement of particle size characteristics of metered dose inhaler
- (MDI) aerosols', Journal of Aerosol Medicine 4(3), 251–263.
- Dong, J., Tian, L. and Ahmadi, G. (2019), 'Numerical assessment of respiratory airway exposure risks to diesel exhaust particles', *Experimental and Computational Multiphase Flow* 1(1), 51–59.
- ⁶⁸⁷ Duan, H.-H., Su, G.-Q., Huang, Y.-C., Song, L.-T. and Nie, S.-D. (2019), 'Segmentation of pul-⁶⁸⁸ monary vascular tree by incorporating vessel enhancement filter and variational region-⁶⁸⁹ growing', *Journal of X-ray science and technology* **27**(2), 343–360.

⁶⁹⁰ Elborn, J. S. (2016), 'Cystic fibrosis', The lancet **388**(10059), 2519–2531.

Engstrom, J. D., Tam, J. M., Miller, M. A., Williams, R. O. and Johnston, K. P. (2009), 'Tem-

⁶⁹² plated open flocs of nanorods for enhanced pulmonary delivery with pressurized metered ⁶⁹³ dose inhalers', *Pharmaceutical research* **26**(1), 101–117.

- Fedorov, A., Beichel, R., Kalpathy-Cramer, J., Finet, J., Fillion-Robin, J.-C., Pujol, S., Bauer,
 C., Jennings, D., Fennessy, F., Sonka, M. et al. (2012), '3d slicer as an image computing
 platform for the quantitative imaging network', *Magnetic resonance imaging* 30(9), 1323–
 1341.
- Germano, M., Piomelli, U., Moin, P. and Cabot, W. H. (1991), 'A dynamic subgrid-scale eddy
 viscosity model', *Physics of Fluids A: Fluid Dynamics* 3(7), 1760–1765.

Gruffydd-Jones, K., Thomas, M., Roman-Rodríguez, M., Infantino, A., FitzGerald, J. M., Pa vord, I., Haddon, J. M., Elsasser, U. and Vogelberg, C. (2019), 'Asthma impacts on work place productivity in employed patients who are symptomatic despite background ther apy: a multinational survey', *Journal of asthma and allergy* 12, 183.

⁷⁰⁴ Gu, Y., Ozel, A., Kolehmainen, J. and Sundaresan, S. (2019), 'Computationally generated
 ⁷⁰⁵ constitutive models for particle phase rheology in gas-fluidized suspensions', *Journal of* ⁷⁰⁶ *Fluid Mechanics* 860, 318–349.

⁷⁰⁷ Gu, Y., Ozel, A. and Sundaresan, S. (2016*a*), 'A modified cohesion model for CFD–DEM ⁷⁰⁸ simulations of fluidization', *Powder technology* **296**, 17–28.

- ⁷⁰⁹ Gu, Y., Ozel, A. and Sundaresan, S. (2016*b*), 'Rheology of granular materials with size distri-
- ⁷¹⁰ butions across dense-flow regimes', *Powder technology* **295**, 322–329.
- Hamaker, H. (1937), 'The london—van der waals attraction between spherical particles',
 physica 4(10), 1058–1072.
- Holbrook, L. T. and Longest, P. W. (2013), 'Validating cfd predictions of highly localized
 aerosol deposition in airway models: In vitro data and effects of surface properties', *Jour- nal of Aerosol Science* 59, 6–21.
- ⁷¹⁶ Inthavong, K., Choi, L.-T., Tu, J., Ding, S. and Thien, F. (2010), 'Micron particle deposition in a
- tracheobronchial airway model under different breathing conditions', Medical engineering

⁷¹⁸ & physics **32**(10), 1198–1212.

⁷¹⁹ Islam, M. S., Paul, G., Ong, H. X., Young, P. M., Gu, Y. and Saha, S. C. (2020), 'A review

of respiratory anatomical development, air flow characterization and particle deposition',
 International Journal of Environmental Research and Public Health 17(2), 380.

- Jan, M. A., Marshall, I. and Douglas, N. J. (1994), 'Effect of posture on upper airway dimensions in normal human.', *American Journal of Respiratory and Critical Care Medicine*149(1), 145–148.
- Jin, H., Fan, J., Zeng, M. and Cen, K. (2007), 'Large eddy simulation of inhaled particle
 deposition within the human upper respiratory tract', *Journal of Aerosol Science* 38(3), 257–
 268.
- Ju, D., Shrimpton, J. and Hearn, A. (2010), 'The effect of reduction of propellant mass fraction on the injection profile of metered dose inhalers', *International journal of pharmaceutics* **391**(1-2), 221–229.

Katsaounou, P., Odemyr, M., Spranger, O., Hyland, M. E., Kroegel, C., Conde, L. G., Gore, R.,
Menzella, F., Ribas, C. D., Morais-Almeida, M. et al. (2018), 'Still fighting for breath: a patient survey of the challenges and impact of severe asthma', *ERJ open research* 4(4), 00076–
2018.

- ⁷³⁵ Khajeh-Hosseini-Dalasm, N. and Longest, P. W. (2015), 'Deposition of particles in the alve-
- olar airways: inhalation and breath-hold with pharmaceutical aerosols', *Journal of aerosol science* **79**, 15–30.
- ⁷³⁸ Kleinstreuer, C., Shi, H. and Zhang, Z. (2007), 'Computational analyses of a pressurized
- ⁷³⁹ metered dose inhaler and a new drug-aerosol targeting methodology', *Journal of Aerosol*
- 740 *Medicine* **20**(3), 294–309. PMID: 17894536.
- 741 URL: https://doi.org/10.1089/jam.2006.0617
- ⁷⁴² Kleinstreuer, C. and Zhang, Z. (2003), 'Targeted drug aerosol deposition analysis for a four ⁷⁴³ generation lung airway model with hemispherical tumors', *Transactions-American Society*

of Mechanical Engineers Journal of Biomechanical Engineering **125**(2), 197–206.

⁷⁴⁵ Kleinstreuer, C. and Zhang, Z. (2010), 'Airflow and particle transport in the human respira-

tory system', Annual review of fluid mechanics **42**, 301–334.

- ⁷⁴⁷ Kloss, C. and Goniva, C. (2011), 'LIGGGHTS-open source discrete element simulations of
 ⁷⁴⁸ granular materials based on LAMMPS', *Supplemental Proceedings: Materials Fabrication*,
 ⁷⁴⁹ *Properties, Characterization, and Modeling* 2, 781–788.
- ⁷⁵⁰ Kloss, C., Goniva, C., Hager, A., Amberger, S. and Pirker, S. (2012), 'Models, algorithms and
 ⁷⁵¹ validation for opensource DEM and CFD–DEM', *Progress in Computational Fluid Dynamics,* ⁷⁵² an International Journal 12(2-3), 140–152.
- Koullapis, P., Kassinos, S. C., Muela, J., Perez-Segarra, C., Rigola, J., Lehmkuhl, O., Cui,
 Y., Sommerfeld, M., Elcner, J., Jicha, M. et al. (2018), 'Regional aerosol deposition in the
 human airways: The siminhale benchmark case and a critical assessment of in silico methods', *European Journal of Pharmaceutical Sciences* 113, 77–94.
- ⁷⁵⁷ Koullapis, P., Ollson, B., Kassinos, S. C. and Sznitman, J. (2019), 'Multiscale in silico lung
 ⁷⁵⁸ modeling strategies for aerosol inhalation therapy and drug delivery', *Current Opinion in* ⁷⁵⁹ *Biomedical Engineering*.
- Lambert, A. R., O'shaughnessy, P. T., Tawhai, M. H., Hoffman, E. A. and Lin, C.-L. (2011),
- ⁷⁶¹ 'Regional deposition of particles in an image-based airway model: large-eddy simulation
- ⁷⁶² and left-right lung ventilation asymmetry', *Aerosol Science and Technology* **45**(1), 11–25.

- ⁷⁶³ Legendre, D., Daniel, C. and Guiraud, P. (2005), 'Experimental study of a drop bouncing on
- ⁷⁶⁴ a wall in a liquid', *Physics of Fluids* **17**(9), 097105.
- Legendre, D., Zenit, R., Daniel, C. and Guiraud, P. (2006), 'A note on the modelling of the
- ⁷⁶⁶ bouncing of spherical drops or solid spheres on a wall in viscous fluid', *Chemical engineer*-
- ⁷⁶⁷ *ing science* **61**(11), 3543–3549.
- Lilly, D. K. (1992), 'A proposed modification of the germano subgrid-scale closure method',
 Physics of Fluids A: Fluid Dynamics 4(3), 633–635.
- Longest, P. W., Hindle, M., Choudhuri, S. D. and Xi, J. (2008), 'Comparison of ambient and
 spray aerosol deposition in a standard induction port and more realistic mouth-throat
 geometry', *Journal of Aerosol Science* 39(7), 572–591.
- Longest, P. W., Tian, G., Walenga, R. L. and Hindle, M. (2012), 'Comparing mdi and dpi
 aerosol deposition using in vitro experiments and a new stochastic individual path (sip)
 model of the conducting airways', *Pharmaceutical research* 29(6), 1670–1688.
- Longest, P. W., Vinchurkar, S. and Martonen, T. (2006), 'Transport and deposition of respiratory aerosols in models of childhood asthma', *Journal of Aerosol Science* 37(10), 1234–1257.

Lu, D., Lee, S. L., Lionberger, R. A., Choi, S., Adams, W., Caramenico, H. N., Chowdhury,
B. A., Conner, D. P., Katial, R., Limb, S. et al. (2015), 'International guidelines for bioequivalence of locally acting orally inhaled drug products: similarities and differences', *The AAPS journal* 17(3), 546–557.

- Ma, B. and Lutchen, K. R. (2006), 'An anatomically based hybrid computational model of
 the human lung and its application to low frequency oscillatory mechanics', *Annals of biomedical engineering* 34(11), 1691–1704.
- Matuttis, H., Luding, S. and Herrmann, H. (2000), 'Discrete element simulations of dense
 packings and heaps made of spherical and non-spherical particles', *Powder technology* 109(1-3), 278–292.
- ⁷⁸⁸ Mayer, D., Bartz, D., Fischer, J., Ley, S., del Rio, A., Thust, S., Kauczor, H. U. and Heussel,

- C. P. (2004), 'Hybrid segmentation and virtual bronchoscopy based on CT images', *Aca- demic Radiology* 11(5), 551–565.
- ⁷⁹¹ McQuaid, E. L., Kopel, S. J., Klein, R. B. and Fritz, G. K. (2003), 'Medication adherence in
- pediatric asthma: reasoning, responsibility, and behavior', *Journal of pediatric psychology*28(5), 323–333.
- Mexichem (n.d.), 'Zephex®134a', Website http://www.mexichemfluor.com/products/medical/zephe
 Accessed 14/05/2019.
- 796 **URL:** *http://www.mexichemfluor.com/products/medical/zephex134a/*
- ⁷⁹⁷ Mitchell, J. P., Nagel, M. W., Wiersema, K. J. and Doyle, C. C. (2003), 'Aerodynamic particle
- ⁷⁹⁸ size analysis of aerosols from pressurized metered-dose inhalers: comparison of ander-
- ⁷⁹⁹ sen 8-stage cascade impactor, next generation pharmaceutical impactor, and model 3321
- aerodynamic particle sizer aerosol spectrometer', *AAPS PharmSciTech* **4**(4), 425–433.
- Miyawaki, S., Tawhai, M. H., Hoffman, E. A. and Lin, C.-L. (2012), 'Effect of carrier gas
 properties on aerosol distribution in a CT-based human airway numerical model', *Annals of biomedical engineering* 40(7), 1495–1507.
- Nardelli, P., Khan, K. A., Corvò, A., Moore, N., Murphy, M. J., Twomey, M., O'Connor,
- O. J., Kennedy, M. P., Estépar, R. S. J., Maher, M. M. et al. (2015), 'Optimizing parameters
 of an open-source airway segmentation algorithm using different CT images', *Biomedical engineering online* 14(1), 62.
- Naseri, A., Shaghaghian, S., Abouali, O. and Ahmadi, G. (2017), 'Numerical investigation of
 transient transport and deposition of microparticles under unsteady inspiratory flow in
 human upper airways', *Respiratory physiology & neurobiology* 244, 56–72.
- Newman, S. P. (2005), 'Principles of metered-dose inhaler design', *Respiratory Care* 50(9), 1177–1190.
- 813 URL: http://rc.rcjournal.com/content/50/9/1177
- Nunes, C., Pereira, A. M. and Morais-Almeida, M. (2017), 'Asthma costs and social impact',
 Asthma Research and Practice 3(1), 1.

- Oakes, J. M., Roth, S. C. and Shadden, S. C. (2018), 'Airflow simulations in infant, child, and 816
- adult pulmonary conducting airways', Annals of biomedical engineering **46**(3), 498–512. 817
- Olsson, B. and Bäckman, P. (2018), Mimetikos preludium™: A new pharma-friendly aerosol 818 drug deposition calculator, in 'Respiratory Drug Delivery'. 819
- Olsson, B., Bondesson, E., Borgström, L., Edsbäcker, S., Eirefelt, S., Ekelund, K., Gustavs-820
- son, L. and Hegelund-Myrbäck, T. (2011), Pulmonary drug metabolism, clearance, and 821
- absorption, in 'Controlled pulmonary drug delivery', Springer, pp. 21–50. 822
- Ozel, A., Gu, Y., Milioli, C. C., Kolehmainen, J. and Sundaresan, S. (2017), 'Towards fil-823 tered drag force model for non-cohesive and cohesive particle-gas flows', *Physics of Fluids* 824 **29**(10), 103308. 825
- Ozel, A., Kolehmainen, J., Radl, S. and Sundaresan, S. (2016), 'Fluid and particle coarsening 826 of drag force for discrete-parcel approach', *Chemical engineering science* **155**, 258–267. 827
- Poorbahrami, K., Mummy, D. G., Fain, S. B. and Oakes, J. M. (2019), 'Patient-specific model-828 ing of aerosol delivery in healthy and asthmatic adults', *Journal of Applied Physiology*.
- Poorbahrami, K. and Oakes, J. M. (2019), 'Regional flow and deposition variability in adult 830
- female lungs: A numerical simulation pilot study', *Clinical Biomechanics* 66, 40–49. 831

829

- Radl, S. and Sundaresan, S. (2014), 'A drag model for filtered euler–lagrange simulations of 832 clustered gas-particle suspensions', Chemical engineering science 117, 416-425. 833
- Ring, N., Booth, H., Wilson, C., Hoskins, G., Pinnock, H., Sheikh, A. and Jepson, R. 834 (2015), 'The 'vicious cycle' of personalised asthma action plan implementation in primary 835 care: a qualitative study of patients and health professionals' views', BMC family practice 836 **16**(1), 145. 837
- Robinson, R. J., Snyder, P. and Oldham, M. J. (2007), 'Comparison of particle tracking algo-838 rithms in commercial CFD packages: sedimentation and diffusion', Inhalation toxicology 839 **19**(6-7), 517–531. 840
- Rubin, B. K. (2007), 'Mucus structure and properties in cystic fibrosis', Paediatric respiratory 841 *reviews* **8**(1), 4–7. 842

Sagaut, P. (2006), Large eddy simulation for incompressible flows: an introduction, Springer Science & Business Media.

Sen, Y., Zhang, Y., Qian, Y. and Morgan, M. (2011), A comparison of medical image segmentation methods for cerebral aneurysm computational hemodynamics, *in* '2011 4th International Conference on Biomedical Engineering and Informatics (BMEI)', Vol. 2, IEEE,
pp. 901–904.

Solomon, P. A., Gehr, P., Bennett, D. H., Phalen, R. F., Méndez, L. B., Rothen-Rutishauser, B.,
Clift, M., Brandenberger, C. and Mühlfeld, C. (2012), 'Macroscopic to microscopic scales
of particle dosimetry: from source to fate in the body', *Air Quality, Atmosphere & Health*5(2), 169–187.

Sundaresan, S., Ozel, A. and Kolehmainen, J. (2018), 'Toward constitutive models for mo mentum, species, and energy transport in gas–particle flows', *Annual review of chemical and biomolecular engineering* 9, 61–81.

Tatsumura, T., Koyama, S., Tsujimoto, M., Kitagawa, M. and Kagamimori, S. (1993), 'Further
study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of
lung carcinomas: fundamental and clinical', *British journal of cancer* 68(6), 1146.

⁸⁵⁹ The Global Asthma Network (2018), 'The Global Asthma Report'.

⁸⁶⁰ Usmani, O. S. (2019), 'Choosing the right inhaler for your asthma or COPD patient', *Thera-* ⁸⁶¹ *peutics and clinical risk management* 15, 461.

⁸⁶² Usmani, O. S., Biddiscombe, M. F. and Barnes, P. J. (2005), 'Regional lung deposition and ⁸⁶³ bronchodilator response as a function of β 2-agonist particle size', *American journal of res-*⁸⁶⁴ *piratory and critical care medicine* **172**(12), 1497–1504.

⁸⁶⁵ Usmani, O. S., Biddiscombe, M. F., Nightingale, J. A., Underwood, S. R. and Barnes, P. J.
 (2003), 'Effects of bronchodilator particle size in asthmatic patients using monodisperse
 ⁸⁶⁷ aerosols', *Journal of Applied Physiology* **95**(5), 2106–2112.

van Holsbeke, C., De Backer, J., Vos, W. and Marshall, J. (2018), 'Use of functional respiratory

imaging to characterize the effect of inhalation profile and particle size on lung deposition

- of inhaled corticosteroid/long-acting β 2-agonists delivered via a pressurized metered-870
- dose inhaler', Therapeutic advances in respiratory disease **12**, 1753466618760948. 871

875

- Verlet, L. (1967), 'Computer" experiments" on classical fluids. i. thermodynamical properties 872 of lennard-jones molecules', Physical review 159(1), 98. 873
- Wang, Y., Chu, K. and Yu, A. (2017), Transport and deposition of cohesive pharmaceutical 874 powders in human airway, in 'EPJ Web of Conferences', Vol. 140, EDP Sciences, p. 08004.
- Watanabe, J. and Watanabe, M. (2019), 'Anatomical factors of human respiratory tract influ-876 encing volume flow rate and number of particles arriving at each bronchus', Biocybernetics 877 and Biomedical Engineering **39**(2), 526–535. 878
- Wei, W., Huang, S.-w., Chen, L.-h., Qi, Y., Qiu, Y.-m. and Li, S.-t. (2017), 'Airflow behavior 879 changes in upper airway caused by different head and neck positions: Comparison by 880 computational fluid dynamics', Journal of biomechanics 52, 89–94. 881
- Weller, H. G., Tabor, G., Jasak, H. and Fureby, C. (1998), 'A tensorial approach to com-882 putational continuum mechanics using object-oriented techniques', Computers in physics 883 12(6), 620–631. 884
- Wittgen, B. P., Kunst, P. W., Van Der Born, K., Van Wijk, A. W., Perkins, W., Pilkiewicz, F. G., 885 Perez-Soler, R., Nicholson, S., Peters, G. J. and Postmus, P. E. (2007), 'Phase i study of 886 aerosolized slit cisplatin in the treatment of patients with carcinoma of the lung', Clinical 887 *cancer research* **13**(8), 2414–2421. 888
- Xi, J., Berlinski, A., Zhou, Y., Greenberg, B. and Ou, X. (2012), 'Breathing resistance and 889 ultrafine particle deposition in nasal-laryngeal airways of a newborn, an infant, a child, 890 and an adult', Annals of biomedical engineering **40**(12), 2579–2595. 891
- Xi, J., Si, X., Kim, J. W. and Berlinski, A. (2011), 'Simulation of airflow and aerosol deposition 892 in the nasal cavity of a 5-year-old child', Journal of Aerosol Science 42(3), 156–173. 893
- Yang, J., Sharp, G., Veeraraghavan, H., van Elmpt, W., Dekker, A., Lustberg, T. and Gooding, 894
- M. (2017), 'Dataset from lung CT segmentation challenge', The Cancer Imaging Archive. 895

- Yang, J., Veeraraghavan, H., Armato III, S. G., Farahani, K., Kirby, J. S., Kalpathy-Kramer,
 J., van Elmpt, W., Dekker, A., Han, X., Feng, X. et al. (2018), 'Autosegmentation for thoracic radiation treatment planning: A grand challenge at AAPM 2017', *Medical physics*45(10), 4568–4581.
- ⁹⁰⁰ Zhang, B., Qi, S., Yue, Y., Shen, J., Li, C., Qian, W. and Wu, J. (2018), 'Particle Disposition in
- the Realistic Airway Tree Models of Subjects with Tracheal Bronchus and COPD', *BioMed research international* 2018.
- ⁹⁰³ Zhang, Z., Kleinstreuer, C. and Hyun, S. (2012), 'Size-change and deposition of conven-⁹⁰⁴ tional and composite cigarette smoke particles during inhalation in a subject-specific air-⁹⁰⁵ way model', *Journal of Aerosol Science* **46**, 34–52.
- ⁹⁰⁶ Zhang, Z., Kleinstreuer, C. and Kim, C. S. (2009), 'Comparison of analytical and cfd mod-
- els with regard to micron particle deposition in a human 16-generation tracheobronchial
- ⁹⁰⁸ airway model', *Journal of Aerosol Science* **40**(1), 16–28.